| abstract |
Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. In particular, provided herein are cetuximab variant anti-EGFR antibodies which are conditionally active in a tumor environment and/or bind EGFR at a lower pH than unmodified cetuximab. Also provided are methods of treatment and uses using modified anti-EGFR antibodies, such as for treatment of a condition responsive to an anti-EGFR antibody (e.g. cancer). |